Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NIPA study
2024-512004-19-01Phase 3Authorised
- Sponsor
- Centre Hospitalier Universitaire de Brest
- Start
- Jul 2024
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Gastrointestinal Dysmotility and ventilator-associated pneumonia (VAP) comparing Naloxegol (Moventig) with Placebo (2 arms). Primary endpoint: Composite primary endpoint: gastrointestinal motility failure or early ventilator-associated pneumonia. Planned start Jul 2024; status: authorised.
02
Drugs
naloxegol
03
Conditions
Gastrointestinal Dysmotilityventilator-associated pneumonia (VAP)
Beyond the preview
Go deeper on 2024-512004-19-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512004-19-01.